IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
Most immunodeficiencies are related to severe immunoglobulin deficiencies which require
lifelong replacement therapy with immunoglobulin G (IgG) to reduce the incidence and severity
of infections. IgG can be administered intravenously (IGIV) every 21 or 28 days or
subcutaneously every week or every other week (IGSC) for subjects who do not tolerate IV
infusions or have difficulties with venous access. No head-to-head data are available to
directly compare HyQvia with conventional SCIG. However, SCIG is indicated for administration
frequencies from daily up to every other week dosing while HyQvia is indicated for infusion
frequencies every 2-4 weeks. This study is designed to assess the IgG trough level after
switching from standard SCIG to every other week HyQvia and HyQvia every 3-4 weeks